Behind Boehringer’s up to $1.3B Nerio deal is a budding cancer pipeline and aim to ‘leapfrog AbbVie’
Boehringer Ingelheim has long been known for its work outside oncology. But since the start of 2019, it’s snapped up more than half a dozen …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
